Heinz Fretz

This inventor holds 19 USPTO granted patents and 4 published patent applications, plus 7 CIPO patents and 16 EPO patents, primarily in PGE2 Receptor Modulation. Top assignees: Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heinz Fretz. Retrieved from https://idiyas.com/inventor/heinz-fretz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 4)

% Patents Active = 42.1

CIPO Patents = 7 (Patent Applications = 5)

EPO Patents = 16 (Patent Applications = 13)

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 78(Granted Patents)

Location History:

Riehen, CH (2009 - 2014)
Allschwil, CH (2013 - 2018)
Gunten, CH (2022 - 2024)

Company Filing History:

12 out of 217

Actelion Pharmaceuticals Ltd

patents

7 out of 81

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2009-2024

Loading Chart...

Areas of Expertise:

PGE2 Receptor

Indole Derivatives

Pyrimidine Derivatives

Phenyl Derivatives

Benzofurane Derivatives

Benzothiophene Derivatives

CXCR7 Modulators

Carbazole Derivatives

Aminopyrazole Derivatives

CRTH2 Antagonists

P2Y12 Antagonists

Neuropeptide FF Antagonists

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12011444 - N-substituted indole derivatives as PGE2 receptor modulators (2024-06-18),

2. 11839613 - Pyrimidine derivatives as PGE2 receptor modulators (2023-12-12),

3. 11712438 - Phenyl derivatives as PGE2 receptor modulators (2023-08-01),

4. 11446298 - Pyrimidine derivatives (2022-09-20),

5. 11325899 - Benzofurane and benzothiophene derivatives as PGE2 receptor modulators (2022-05-10),

6. 11241431 - N-substituted indole derivatives as PGE2 receptor modulators (2022-02-08),

7. 9920010 - CXCR7 receptor modulators (2018-03-20),

8. 9428456 - 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives (2016-08-30),

9. 8697869 - 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators (2014-04-15),

10. 8575158 - [object Object] (2013-11-05),

11. 8288419 - Aminopyrazole derivatives (2012-10-16),

12. 8273740 - 2-sulfanyl-benzoimidazol-1-yi-acetic acid derivatives as CRTH2 antagonists (2012-09-25),

13. 8143304 - [object Object] (2012-03-27),

14. 8048881 - Pyrimidine derivatives and their use as P2Y12 receptor antagonists (2011-11-01),

15. 8039474 - [object Object] (2011-10-18),

Title: The Innovative Journey of Inventor Heinz Fretz

Introduction

Heinz Fretz, a prolific inventor based in Riehen, Switzerland, is renowned for his contributions to pharmaceutical innovations. With an impressive portfolio of 19 patents, Fretz has dedicated his career to developing novel compounds that have the potential to significantly impact medical treatments.

Latest Patents

Fretz's recent patents showcase his expertise in developing derivatives that function as modulators for critical receptors involved in various health conditions. One notable invention involves N-substituted indole derivatives designed as PGE2 receptor modulators. This invention includes detailed formulations, preparation methods, and potential pharmaceutical applications, particularly in relation to prostaglandin E2 receptors EP2 and EP4. Another significant contribution is his work on pyrimidine derivatives that modulate the immune response in cancer treatment. This patent elucidates the therapeutic potential of these compounds in reactivating the immune system against tumors, alongside novel benzofurane and benzothiophene derivatives.

Career Highlights

Throughout his career, Heinz Fretz has worked with major pharmaceutical companies, including Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. His role in these organizations has facilitated advancements in drug development and innovative treatment modalities, making a substantial impact in the pharmaceutical industry.

Collaborations

Fretz has collaborated with several talented professionals, most notably Sylvia Richard-Bildstein and Julien Pothier. These partnerships have fostered an environment of innovation and creativity, contributing to the success of various projects and patents.

Conclusion

Heinz Fretz represents a valuable asset in the field of pharmaceuticals through his innovative inventions and dedication to advancing medical science. His commitment to research and development continues to inspire future innovations in healthcare. The discoveries stemming from his patents hold immense promise for treating complex diseases and improving patient outcomes.

Profile summary based on public USPTO records.